Speakers - Sachs Associates

CONTACT
Tom Johnston
Chief Executive Officer
ADDRESS
Mucosis B.V.
L.J. Zielstraweg 1
9713 GX, Groningen
The Netherlands
TELEPHONE
+31 (50) 8200050 (T)
+31 (6) 55320948 (M)
FAX
+31 (50) 8200051
EMAIL
tom.johnston@mucosis.com
YEAR FOUNDED
2006
Mucosis B.V.
www.mucosis.com
FINANCIAL SUMMARY
Series A: €3,000,000 (2007)
Inn.Credit: €3,000,000 (2010)
Current Investors: • Biogeneration Ventures • MedSciences Capital • N.V. NOM
COMPANY PROFILE
About Mucosis
Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath, on which it
develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM, a vaccine to prevent
influenza; PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM, a
vaccine to prevent RSV viral infections. Mimopath-based vaccines can be administered needle-free in the
nose and mouth, evoking a more natural immune response with a broader base of protection.
About Mimopath technology
The Mimopath technology is based on Lactococcus lactis, a safe bacterium commonly used in the food
industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacteriumlike
particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigencovered
BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These
vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
MANAGEMENT
Senior Management
Thomas Johnston, CEO
Kees Leenhouts, CSO
Roberto Grimaldi, CMO
Jolande Schoemaker, QA-officer & Qualified Person
Board of Directors
John Lambert, Chairman
Barry Buckland
Annemieke Wouterse
Willem Hazenberg
Otto Postma
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS